Skip to main content
    P

    Pyxis Oncology Inc (PYXS)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $1.41
    -0.17 (-10.76%)

    Market Cap: $188.98M

    Last updated: Nov 17, 2026 at 11:05 AM ET

    Pyxis Oncology Inc (PYXS) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Pyxis Oncology are Compass Therapeutics (CMPX), PolyPid (PYPD) and Innate Pharma (IPHA). By market cap, Pyxis Oncology ranks 6th of the 13 companies on this page; Prelude Therapeutics (PRLD) is the largest at $275.32M.

    Peer Comparison

    PYXS's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Pyxis Oncology (PYXS)$188.98MN/A11.6x0.0%N/A0.0%0.00%
    Compass Therapeutics Inc. (CMPX)$139.35MN/AN/A0.0%N/A0.0%0.00%
    PolyPid (PYPD)$132.25MN/AN/A0.0%N/A0.0%0.00%
    Innate Pharma (IPHA)$154.15MN/A17.6x0.0%489.8%16.5%0.00%
    Protalix Biotherapeutics Inc (PLX)$257.17M12.1x2.9x24.3%N/A22.8%0.00%
    Keros Therapeutics Inc (KROS)$202.13MN/A4.9x-151.4%N/A180.5%0.00%
    Invivyd Inc. (IVVD)$171.58MN/A2.9x-183.9%N/A21.2%0.00%
    Protara Therapeutics Inc (TARA)$155.77MN/AN/A0.0%N/A0.0%0.00%
    Prelude Therapeutics Inc (PRLD)$275.32MN/A16.3x-269.7%N/A41.0%0.00%
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)$141.66MN/AN/A0.0%N/A-100.0%0.00%
    MacroGenics Inc (MGNX)$140.60MN/A1.2x-36.6%-108.7%-64.8%0.00%
    Greenwich Lifesciences Inc (GLSI)$219.29MN/AN/A0.0%N/A0.0%0.00%
    Rocket Pharmaceuticals Inc (RCKT)$256.82MN/AN/A0.0%-2.3%0.0%0.00%
    Peer median$163.68M12.1x3.9x0.0%-2.3%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Pyxis Oncology, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Compass Therapeutics Inc. (CMPX)
    Compass Therapeutics, Inc. is a clinical-stage oncology-focused biopharmaceutical company developing proprietary antibody-based therapies to treat multiple...
    CMPX competitors
    PolyPid (PYPD)
    PolyPid Ltd., an advanced stage biopharmaceutical company, develops, manufactures and markets products based on the Polymer Lipid Encapsulation Matrix (PLEX)...
    PYPD competitors
    Innate Pharma (IPHA)
    Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France...
    Protalix Biotherapeutics Inc (PLX)
    Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its...
    PLX competitors
    Keros Therapeutics Inc (KROS)
    Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery...
    KROS competitors
    Invivyd Inc. (IVVD)
    Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery...
    IVVD competitors
    Protara Therapeutics Inc (TARA)
    Protara Therapeutics, Inc., a clinical-stage biopharmaceutical company, is dedicated to identifying and promoting transformative therapies for the treatment...
    TARA competitors
    Prelude Therapeutics Inc (PRLD)
    Prelude Therapeutics Incorporated, a precision clinical-stage oncology company, focuses on the discovery and development of small molecule therapies optimized...
    PRLD competitors
    NeOnc Technologies Holdings, Inc. Common Stock (NTHI)
    NeOnc Technologies Holdings, Inc. is a pioneering biotechnology firm dedicated to revolutionizing cancer treatment through its advanced immunotherapy...
    NTHI competitors
    MacroGenics Inc (MGNX)
    MacroGenics, Inc., a biopharmaceutical company, discovers and develops antibody-based therapies to treat cancer in the United States.
    MGNX competitors
    Greenwich Lifesciences Inc (GLSI)
    Greenwich LifeSciences, Inc., a clinical-stage biopharmaceutical company, focuses on the development of new cancer immunotherapies for breast and other HER2 /...
    GLSI competitors
    Rocket Pharmaceuticals Inc (RCKT)
    Rocket Pharmaceuticals, Inc., is a cross-platform biotechnology company focused on developing gene therapies for rare and devastating pediatric diseases.
    RCKT competitors

    Frequently Asked Questions About PYXS

    Who are Pyxis Oncology's main competitors?

    The companies most similar to Pyxis Oncology include Compass Therapeutics (CMPX), PolyPid (PYPD), Innate Pharma (IPHA), Protalix Biotherapeutics (PLX) and Keros Therapeutics (KROS), listed from the closest match.

    Who is Pyxis Oncology's biggest competitor?

    Prelude Therapeutics (PRLD) is the largest of the similar companies at $275.32M; Compass Therapeutics (CMPX) is the closest match by business profile, size, sector and industry.

    How does PYXS stock compare with its competitors?

    PYXS' P/S is 11.6x against a peer median of 3.9x; its net margin is 0.0% against a peer median of 0.0%.

    Which of Pyxis Oncology's competitors pays a higher dividend?

    Pyxis Oncology pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Pyxis Oncology bigger than its competitors?

    No. Pyxis Oncology is 6th by market cap among the 13 companies on this page; the largest is Prelude Therapeutics (PRLD) at $275.32M.